Clinical Trial Update: Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a neoantigen-based peptide vaccine in combination with a PD-1 inhibitor and radiotherapy for advanced non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Neoantigen-based Peptide Vaccine
• PD-1 inhibitor

Snippet

Sponsor: The First Affiliated Hospital of Nanchang University | Conditions: Advanced NSCLC | Phase 2 | Status: RECRUITING